Xueqing Li

Cooley advised Reata Pharmaceuticals on a $275 million debt financing from funds managed by Pharmakon Advisors, and on an amendment and restatement of its development and commercialization funding agreement with affiliates of Blackstone Life Sciences. Reata – a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases –trades on the Nasdaq Global Market under the symbol RETA. Lawyers Michael Tollini, Mischi a Marca, Addison Pierce, Kelsey Watkins and Xueqing Li led the Cooley team.

Cooley advised affiliates of Fernweh Group on its definitive agreement with AZZ. Lawyers Ian Nussbaum and Bill Roegge led the Cooley team advising Fernweh.

Cooley advised Vera Therapeutics on its $50 Million debt facility with Oxford Finance. Vera, whose shares trade on the Nasdaq Global Market under the symbol VERA, is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Partner Patrick Flanagan led the Cooley team.

Cooley advised Dynavax Technologies on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. Dynavax Technologies, whose securities trade on the Nasdaq Capital Market under the symbol DVAX, is a biopharmaceutical company focused on developing and commercializing novel vaccines. Partners Steve Przesmicki, Mischi a Marca and Jason Savich le the Cooley team.